Navigation Links
Human Genome Sciences Presents Results of Phase 2 Trial of Albuferon(R) in Chronic Hepatitis C Patients Who Failed To Respond To Previous Therapy
Date:11/5/2007

y of life results from the Phase 2b clinical trial of Albuferon (Pianko, et al), click here. To view the AASLD oral presentation reporting results of the Phase 2 trial of Albuferon in non- responders (Nelson, et al), click here. To view the AASLD poster presentation reporting results of a prospective comparison of commercial fibrosis serum marker panels (Patel, et al), click here. For more information about Albuferon, please visit http://www.hgsi.com/products/albuferon.html. Health professionals or patients interested in Albuferon clinical trials or other studies involving HGS products may inquire via the "Contact Us" section of the Company's web site, http://www.hgsi.com/products/request.html, or by calling (301) 610-5790, extension 3550.

HGS, Human Genome Sciences, ABthrax, Albuferon and LymphoStat-B are trademarks of Human Genome Sciences, Inc.

Safe Harbor Statement

This announcement contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The forward-looking statements are based on Human Genome Sciences' current intent, belief and expectations. These statements are not guarantees of future performance and are subject to certain risks and uncertainties that are difficult to predict. Actual results may differ materially from these forward-looking statements because of the Company's unproven business model, its dependence on new technologies, the uncertainty and timing of clinical trials, the Company's ability to develop and commercialize products, its dependence on collaborators for services and revenue, its substantial indebtedness and lease obligations, its changing requirements and costs associated with facilities, intense competition, the uncertainty of patent and intellectual prop
'/>"/>

SOURCE Human Genome Sciences, Inc.
Copyright©2007 PR Newswire.
All rights reserved

2

GOOD

Page: 1 2 3 4 5 6

Related medicine technology :

1. Video: New Research Discovers Independent Brain Networks Control Human Walking
2. Lpath Demonstrates Strong Safety Profile of Lead Drug Candidate, Sphingomab(TM), in Non-Human Primates
3. Enrollment Begins on Human PK Study for Medidur(TM) FA
4. Human Genome Sciences Completes Enrollment of First Phase 3 Albuferon(R) Trial Ahead of Schedule
5. Study Confirms Limited Human-To-Human Spread of Avian-Flu Virus in Indonesia in 2006
6. Lpath Demonstrates Preclinical Efficacy of Lpathomab(TM) and Initiates Humanization Process
7. Peregrine Researchers Report Data Showing Bavituximabs Potential to Shrink Human Prostate Tumors in Model of Relapsed Disease
8. Dr. Roger Kenneth Hershline PhD MD, CEO of Global Humanceuticals, Inc. Donates New HIV Drug
9. Study Shows Plasma-Derived Human Thrombin Equivalent to Bovine Thrombin in Achieving Hemostasis in Surgery
10. Tengion Launches Second Phase 2 Clinical Trial of Regenerated Human Organ
11. Flexible Medical Systems Raises $1.2M Seed Investment for Initial Human Trials
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/17/2013)... Ill. , May 17, 2013  Sony Biotechnology Inc. ... Sorter 8-well strip holder and 130um sorting chip.  Sony will ... collected on its new SH800 Cell Sorter, the EC800 flow ... commercial tutorials at CYTO 2013, which will be held at ... San Diego, California , from May 20 ...
(Date:5/17/2013)... 2013  TechAtlas Group has announced the release ... map for the Chronic Kidney Disease (CKD) market. ... with drugs and devices currently on the market ... (Logo:  http://photos.prnewswire.com/prnh/20130517/NE16011LOGO ) ... - renal denervation , diabetic nephropathy - ...
(Date:5/17/2013)... Fuse Science, Inc. (OTCQB: DROP), ( www.fusescience.com ) ... new, patent-pending technologies poised to redefine how consumers receive energy, ... a business update teleconference and webcast for shareholders and the ... 4:30 PM ET. Fuse Science, Inc. CEO, ... and will be joined by Rubin Hanan ...
Breaking Medicine Technology:Sony Delivers New Technology for Science to CYTO 2013 2TechAtlas Group Releases Innovative Chronic Kidney Disease Landscape Map 2Fuse Science, Inc. to Hold Business Update Webcast and Teleconference on May 22nd 2
... Vanda Pharmaceuticals Inc. (NASDAQ: VNDA ... affiliate of Vanda,s sublicensor Novartis Pharma AG, has ... injectable (or depot) formulation of Fanapt® (iloperidone).  This ... the safety and pharmacokinetic profiles of two different ...
... ROME, April 8, 2011 Noverca – the first and ... offerings by announcing its presence in the Health and ... to support diabetes treatment has been developed and launched thanks ... of N o verca) and Fatebenefratelli ...
Cached Medicine Technology:Vanda Pharmaceuticals Announces Commencement of Clinical Study of Long-Acting Injectable Formulation of Fanapt® 2Vanda Pharmaceuticals Announces Commencement of Clinical Study of Long-Acting Injectable Formulation of Fanapt® 3EXTENDED HEALTH: Noverca Enters the World of Healthcare 2
(Date:5/18/2013)... Utah (PRWEB) May 18, 2013 ... on insurance agents’ role in Marketplaces . ... to traditional employer sponsored health benefits, is the ... and health reimbursement arrangements . , ... Health and Human Services (HHS) recently released a ...
(Date:5/18/2013)... The “World Healthcare IT Market: Trends & Forecast (2010 ... restraints, and opportunities in North America, Europe, Asia, & ... 89 market data tables , ... , http://www.marketsandmarkets.com/Market-Reports/healthcare-information-technology-market-136.html , Early buyers ... healthcare IT market is expected to grow from $99.6 ...
(Date:5/18/2013)... York, New York (PRWEB) May 18, 2013 ... to mount in courts throughout the country, Bernstein Liebhard ... metal-on-metal hip replacement patients often suffer tissue damage before ... the study, which according to Science Daily will appear ... metal-on-metal hip replacement recipients underwent MRI screens of their ...
(Date:5/18/2013)... The “Sleep Apnea Diagnostic & Therapeutic Devices ... Servo-Ventilation (ASV), Oral Appliances, Nasal EPAP, Neurostimulation] Global End-user ... studies the major market drivers, restraints, and opportunities in ... , Browse , 147 market ... , 318 pagesand in-depth TOC of ...
(Date:5/18/2013)... The Ayurvedic practitioner program will be offered ... West. Program is available in Mexico via Live Internet ... modality practiced for over 5,000 years. In Ayurvedic medicine ... begins when an individual lives in harmony with their ... Ayurveda aims to heal an individual in all levels ...
Breaking Medicine News(10 mins):Health News:Zane Benefits Publishes New Information on Insurance Agents’ Role in Marketplaces 2Health News:Zane Benefits Publishes New Information on Insurance Agents’ Role in Marketplaces 3Health News:Zane Benefits Publishes New Information on Insurance Agents’ Role in Marketplaces 4Health News:Healthcare IT Market to reach US$ 162.2 Billion by 2015 at a CAGR of 10.2% - New Report by MarketandMarkets 2Health News:Healthcare IT Market to reach US$ 162.2 Billion by 2015 at a CAGR of 10.2% - New Report by MarketandMarkets 3Health News:Metal-on-Metal Hip Implants: Bernstein Liebhard LLP Comments on New Study Finding that Tissue Damage Precedes Pain in Metal-on-Metal Hip Replacement Patients 2Health News:Metal-on-Metal Hip Implants: Bernstein Liebhard LLP Comments on New Study Finding that Tissue Damage Precedes Pain in Metal-on-Metal Hip Replacement Patients 3Health News:Metal-on-Metal Hip Implants: Bernstein Liebhard LLP Comments on New Study Finding that Tissue Damage Precedes Pain in Metal-on-Metal Hip Replacement Patients 4Health News:Sleep Apnea Devices Market to reach $19.72 Billion by 2017 - New Report by MarketandMarkets 2Health News:Sleep Apnea Devices Market to reach $19.72 Billion by 2017 - New Report by MarketandMarkets 3Health News:Ayurveda Training in Mexico Offered by Escuela de Ayurveda de California, a Leading Institution in the West 2
... 29 Varian Medical,Systems (NYSE: VAR ) ... equipment for a major new hospital in,Portsmouth, England. ... the investment waves of the UK government,s Cancer ... will receive four high-energy,Clinac(R) iX linear accelerators equipped ...
... American Legacy Foundation(R) Finds Tobacco-Free,States Spend Less on ... could spend nearly $10 billion less within five ... new study released today by the,American Legacy Foundation ... cut Medicaid costs by 5.6 percent., The ...
... of the hip is a growing problem that will ... have reported on risk factors for developing OA, but ... prognosis. A new study published in the December issue ... patients with hip pain to determine their disease progression ...
... (NYSE:,CNO) said today that it has agreed to implement a ... (LTCG) for certain,back-office functions of the long term care business ... year that it was,considering this solution. Under the agreement:, ... call center and the processing ...
... Nov. 29, WASHINGTON, Nov. 28 The following ... WHAT: A press briefing by conference call with experts ... as recently issued,proposals by several of the candidates for ... the new estimates of the AIDS crisis mean for ...
... in a key piece of DNA seem important, scientists say ... contribute to disparities in colorectal cancer rates between ethnic and ... team, led by investigators at the University of Pittsburgh, analyzed ... found that people who have two "T" copies of the ...
Cached Medicine News:Health News:Varian Image-Guided Treatment Machines Selected for Major New Hospital on South Coast of England 2Health News:Varian Image-Guided Treatment Machines Selected for Major New Hospital on South Coast of England 3Health News:Smokers Cost Medicaid System Nearly $10 Billion 2Health News:Smokers Cost Medicaid System Nearly $10 Billion 3Health News:Identifying patients at high risk for total hip replacement 2Health News:Conseco to Implement Systems and Operational Solution From Long Term Care Group 2Health News:Conseco to Implement Systems and Operational Solution From Long Term Care Group 3Health News:Conseco to Implement Systems and Operational Solution From Long Term Care Group 4Health News:Conseco to Implement Systems and Operational Solution From Long Term Care Group 5Health News:Genes May Explain Role of Race in Colon Cancer Risk 2
... single use, disposable device that is specifically ... after the needle is in place. ,It ... from accidental movement by contact, during patient ... patient confidence in your staff and your ...
... for high volume laboratories, the AU2700 automates ... time. This high-speed analyzer delivers true random ... test results per hour (up to 2133 ... tests on-board. Consolidate with Olympus 122 test ...
... The EPO ELISA is intended for the ... This assay is intended for in vitro diagnostic ... anemias and polycythemias. With the advent of the ... to increase red blood cell mass, an erythropoietin ...
... innovative PoleStar N20, exclusively distributed by ... MRI. Combining intra-operative imaging with ... system, PoleStar N20 is one of ... today. , , Exceptional image quality ...
Medicine Products: